In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni.
Morbidity and mortality caused by schistosomiasis are serious public health problems in developing countries. Because praziquantel is the only drug in therapeutic use, the risk of drug resistance is a concern. In the search for new schistosomicidal drugs, we performed a target-based chemogenomics sc...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC4287566?pdf=render |
id |
doaj-2da02339d91d4fb483b590ad5f679ffc |
---|---|
record_format |
Article |
spelling |
doaj-2da02339d91d4fb483b590ad5f679ffc2020-11-25T01:38:43ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352015-01-0191e343510.1371/journal.pntd.0003435In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni.Bruno J NevesRodolpho C BragaJosé C B BezerraPedro V L CravoCarolina H AndradeMorbidity and mortality caused by schistosomiasis are serious public health problems in developing countries. Because praziquantel is the only drug in therapeutic use, the risk of drug resistance is a concern. In the search for new schistosomicidal drugs, we performed a target-based chemogenomics screen of a dataset of 2,114 proteins to identify drugs that are approved for clinical use in humans that may be active against multiple life stages of Schistosoma mansoni. Each of these proteins was treated as a potential drug target, and its amino acid sequence was used to interrogate three databases: Therapeutic Target Database (TTD), DrugBank and STITCH. Predicted drug-target interactions were refined using a combination of approaches, including pairwise alignment, conservation state of functional regions and chemical space analysis. To validate our strategy, several drugs previously shown to be active against Schistosoma species were correctly predicted, such as clonazepam, auranofin, nifedipine, and artesunate. We were also able to identify 115 drugs that have not yet been experimentally tested against schistosomes and that require further assessment. Some examples are aprindine, gentamicin, clotrimazole, tetrabenazine, griseofulvin, and cinnarizine. In conclusion, we have developed a systematic and focused computer-aided approach to propose approved drugs that may warrant testing and/or serve as lead compounds for the design of new drugs against schistosomes.http://europepmc.org/articles/PMC4287566?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bruno J Neves Rodolpho C Braga José C B Bezerra Pedro V L Cravo Carolina H Andrade |
spellingShingle |
Bruno J Neves Rodolpho C Braga José C B Bezerra Pedro V L Cravo Carolina H Andrade In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. PLoS Neglected Tropical Diseases |
author_facet |
Bruno J Neves Rodolpho C Braga José C B Bezerra Pedro V L Cravo Carolina H Andrade |
author_sort |
Bruno J Neves |
title |
In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. |
title_short |
In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. |
title_full |
In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. |
title_fullStr |
In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. |
title_full_unstemmed |
In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. |
title_sort |
in silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of schistosoma mansoni. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Neglected Tropical Diseases |
issn |
1935-2727 1935-2735 |
publishDate |
2015-01-01 |
description |
Morbidity and mortality caused by schistosomiasis are serious public health problems in developing countries. Because praziquantel is the only drug in therapeutic use, the risk of drug resistance is a concern. In the search for new schistosomicidal drugs, we performed a target-based chemogenomics screen of a dataset of 2,114 proteins to identify drugs that are approved for clinical use in humans that may be active against multiple life stages of Schistosoma mansoni. Each of these proteins was treated as a potential drug target, and its amino acid sequence was used to interrogate three databases: Therapeutic Target Database (TTD), DrugBank and STITCH. Predicted drug-target interactions were refined using a combination of approaches, including pairwise alignment, conservation state of functional regions and chemical space analysis. To validate our strategy, several drugs previously shown to be active against Schistosoma species were correctly predicted, such as clonazepam, auranofin, nifedipine, and artesunate. We were also able to identify 115 drugs that have not yet been experimentally tested against schistosomes and that require further assessment. Some examples are aprindine, gentamicin, clotrimazole, tetrabenazine, griseofulvin, and cinnarizine. In conclusion, we have developed a systematic and focused computer-aided approach to propose approved drugs that may warrant testing and/or serve as lead compounds for the design of new drugs against schistosomes. |
url |
http://europepmc.org/articles/PMC4287566?pdf=render |
work_keys_str_mv |
AT brunojneves insilicorepositioningchemogenomicsstrategyidentifiesnewdrugswithpotentialactivityagainstmultiplelifestagesofschistosomamansoni AT rodolphocbraga insilicorepositioningchemogenomicsstrategyidentifiesnewdrugswithpotentialactivityagainstmultiplelifestagesofschistosomamansoni AT josecbbezerra insilicorepositioningchemogenomicsstrategyidentifiesnewdrugswithpotentialactivityagainstmultiplelifestagesofschistosomamansoni AT pedrovlcravo insilicorepositioningchemogenomicsstrategyidentifiesnewdrugswithpotentialactivityagainstmultiplelifestagesofschistosomamansoni AT carolinahandrade insilicorepositioningchemogenomicsstrategyidentifiesnewdrugswithpotentialactivityagainstmultiplelifestagesofschistosomamansoni |
_version_ |
1725051921243308032 |